Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has started large-scale production of Nanologica’s silica particles.
Oval Medical Technologies Limited (Oval), a leader of patient-centric autoinjectors, has signalled a new stage in its growth with a move to a purpose-designed facility in Cambridge Research Park, U.K.
Particle Testing Authority (PTA), a division of Micromeritics Instrument Corporation, has stepped up its Pore Analysis Capabilities. The Company recently announced those efforts include capillary flow porometery (CFP) and liquid-liquid displacement porometry (LLDP).
Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership to study and develop unique strategies to treat pancreatic cancer.
Latest development at Dublin site positions it at forefront of EU operations, supporting European expansion and robust Brexit plan for continuity of pharmaceutical supply
Pfizer announced recently an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.
Thermo Fisher recently expanded their steriles capabilities to support clients requiring auto-injector devices for patient self-administration. Located in dedicated and flexible GMP-compliant cabins, Thermo Fisher can accommodate both small and multi-million unit runs. This further increases the company’s breadth of sterile services, which also includes cartridge and vial fill-finish, prefilled syringe assembly, primary and secondary packaging, and label services.
Thermo Fisher will dedicate its newly installed training center, designed with industry-leading resources and technologies. The facility is equipped with virtual reality and augmented reality capabilities, which will mimic a real-world operating environment and equipment, and reduce the amount of training time by 50%.
The purpose built, state-of-the art facility will help address the growing demand for development supply chain services and will focus on high quality secondary packaging solutions for customers and their patients. The new site will provide clinical trial support services including GMP storage, local labeling, secondary packaging, comparator sourcing, and handling and distribution of ambient and cold chain clinical trial supplies through to returns management.
Thermo Fisher Scientific expanded capacity at the North American site for sterile drug products in Greenville, NC and will now perform non-GMP work to support clinical phase programs. The new development laboratory features two Lyostar3 freeze dryers with SMART technology that are capable of decreasing the number of runs required for lyophilization cycle development.
|
|
|
|
|
|
|
|
|